Last updated: November 9, 2026
DigiFab is a niche emergency medicine containing ovine digoxin immune Fab for life-threatening or potentially life-threatening digoxin toxicity and overdose. Its commercial value comes from clinical necessity, limited therapeutic substitutes, hospital stocking requirements, and a small supplier base rather than high prescription volume. Public sources do not disclose DigiFab-specific revenue, profit, or unit sales. The product’s financial trajectory is therefore best assessed through market structure, regulatory barriers, ownership history, supply conditions, and demand drivers.
What is DigiFab and how is it used?
DigiFab is an intravenous preparation of purified ovine antibody fragments that bind digoxin and related cardiac glycosides. Each 40-mg vial neutralizes approximately 0.5 mg of digoxin, subject to the dose and serum concentration calculations in the prescribing information.
The product is used in emergency departments, intensive-care units, poison-control settings, and hospitals treating:
- Life-threatening digoxin toxicity
- Acute digoxin overdose
- Cardiac arrhythmias associated with excessive digoxin exposure
- Hyperkalemia associated with severe acute toxicity
DigiFab is generally administered in a hospital because patients require cardiac monitoring and management of arrhythmias, electrolyte abnormalities, renal dysfunction, and rebound toxicity.
| Attribute |
DigiFab |
| Active ingredient |
Digoxin immune Fab, ovine |
| Dosage form |
Intravenous injection |
| Strength |
40 mg per vial |
| FDA pathway |
New Drug Application 021626 |
| Therapeutic category |
Antidote and emergency toxicology |
| Primary manufacturer and rights holder |
SERB Pharmaceuticals |
| Main use |
Life-threatening digoxin toxicity and overdose |
| Commercial channel |
Hospital, emergency-care, and specialty distribution |
| Biosimilar pathway |
Not commercially relevant to current competition |
| Retail prescription exposure |
Minimal |
The FDA approved DigiFab in the United States in 2001. Its predecessor, Digibind, had been used for the same clinical purpose, but DigiFab became the principal U.S. product after Digibind was discontinued.[1]
Who owns DigiFab and how has ownership changed?
DigiFab was historically associated with BTG Pharmaceuticals. Boston Scientific acquired BTG in 2019, including BTG’s specialty pharmaceutical portfolio. SERB Pharmaceuticals later acquired BTG’s specialty pharmaceutical business from Boston Scientific in a transaction announced in 2021.[2][3]
The ownership sequence is commercially important because DigiFab is part of a specialty pharmaceutical portfolio rather than Boston Scientific’s core medical-device business.
| Period |
Owner or commercial sponsor |
Strategic position |
| Before 2019 |
BTG Pharmaceuticals |
Specialty antidote and critical-care portfolio |
| 2019-2021 |
Boston Scientific |
Acquired BTG; later divested specialty pharmaceuticals |
| From 2021 |
SERB Pharmaceuticals |
Specialty pharmaceutical and emergency-medicine platform |
SERB’s portfolio includes products used in acute care, toxicology, and rare emergency conditions. DigiFab fits that strategy because hospitals may need to maintain supply even when annual utilization is low.
What drives demand for DigiFab?
DigiFab demand is driven by clinical severity rather than routine prescribing. Five factors determine the market:
- Digoxin utilization and toxicity incidence
- Accidental and intentional overdose volume
- Hospital stocking policies
- Product availability and supply continuity
- The absence of a broadly accepted substitute for severe cases
Digoxin prescribing has declined in some cardiovascular indications because of competition from newer heart-failure and rhythm-management therapies. That decline can reduce the underlying number of toxicity cases. Demand remains because digoxin continues to be used in selected patients with atrial fibrillation, heart failure, and other cardiac conditions, particularly among older patients and those with renal impairment.
Toxicity risk is higher when renal clearance is impaired, dosing is excessive, drug interactions occur, or serum potassium levels change. Acute ingestion can produce severe toxicity even when chronic digoxin use is limited.
The market has a distinctive inventory dynamic. Hospitals must balance the high cost of keeping antidote stock against the clinical risk of not having it when a severe poisoning occurs. Poison-control centers and regional hospital systems may influence purchasing because DigiFab can be transferred or allocated during an emergency.
How large is the DigiFab market and what is the financial trajectory?
No public filing identified here reports DigiFab-specific revenue, gross margin, units sold, or EBITDA. SERB is privately held, and prior public-company disclosures did not consistently provide a standalone DigiFab revenue line. Market-size estimates that assign a precise annual revenue figure to DigiFab should therefore be treated as model-based rather than reported financial data.
The financial trajectory is likely characterized by stable-to-variable demand, high revenue per treated case, and low volume. The major commercial features are:
- Low prescription frequency compared with mass-market medicines
- High clinical value per emergency treatment
- Hospital purchasing and inventory exposure
- Potential revenue volatility from poisoning clusters, supply interruptions, and stocking changes
- Limited price sensitivity in a life-threatening emergency
- Manufacturing complexity associated with animal-derived antibody fragments
The product’s revenue is likely more sensitive to price, vial utilization, contracting, and hospital formulary decisions than to broad patient-market expansion. A patient may require multiple vials, and the treatment cost can rise materially in large overdoses or when the ingested dose is uncertain.
Base-case financial outlook
The base case is a mature specialty-antidote business with relatively stable demand and limited volume growth. Revenue can remain resilient if SERB maintains supply reliability, hospital contracts, and favorable emergency-department access.
Upside factors
Potential upside comes from:
- Higher digoxin toxicity awareness
- More consistent hospital stocking
- Increased use in poison-control protocols
- Price increases in a concentrated market
- Supply disruption affecting alternative products
- Expansion of emergency-medicine distribution networks
Downside factors
Potential downside comes from:
- Continued decline in digoxin prescribing
- Generic or competing digoxin immune Fab supply
- Hospital cost-containment programs
- Reduced inventory levels
- Manufacturing interruptions
- Expanded use of non-Fab supportive care in less severe toxicity
When does DigiFab lose exclusivity?
DigiFab’s principal U.S. regulatory and commercial protections are mature. The product received FDA approval in 2001, so any ordinary new-drug exclusivity associated with the original approval expired long ago.[1]
The key distinction is between regulatory exclusivity and patent protection:
| Protection |
DigiFab position |
| Original FDA marketing exclusivity |
Expired |
| New chemical entity exclusivity |
Not commercially relevant today |
| Orphan-drug exclusivity |
No current commercial relevance identified |
| Patent term tied to original launch |
Mature and unlikely to block entry |
| Manufacturing know-how |
Potentially more important than expired composition patents |
| Hospital and distribution relationships |
Commercial barrier |
| FDA approval of a competing product |
Primary remaining entry event |
DigiFab’s main defenses are therefore likely to be manufacturing capability, regulatory execution, supply reliability, clinical familiarity, and access to hospital channels. The business is less dependent on a long-dated patent monopoly than on the difficulty of reproducing and validating an animal-derived antibody-fragment product.
What patents protect DigiFab?
No commercially material active U.S. patent position is evident from the public product information cited for this analysis. The principal intellectual-property barriers are more likely to involve:
- Production of ovine antibody fragments
- Immunization and antibody-harvesting processes
- Purification and viral-safety controls
- Formulation and stability
- Analytical characterization
- Consistency of potency and digoxin-binding activity
- Manufacturing scale and release testing
The product’s age limits the strategic value of original composition-of-matter patents. Any surviving patent protection would need to cover a specific manufacturing process, formulation, dosing method, or other narrow feature to create a meaningful entry barrier.
What formulations are protected by DigiFab patents?
DigiFab is supplied as a sterile injectable product for intravenous administration. The commercial formulation itself is important operationally, but the available public record cited here does not establish a current, enforceable formulation-patent barrier.
A competing product would still need to demonstrate suitable stability, sterility, potency, purity, and immunogenicity characteristics. Those requirements can delay entry even when formal patent barriers are weak.
What is the Orange Book status of DigiFab?
DigiFab was approved under NDA 021626 rather than through a modern biosimilar pathway. The relevant competitive question is whether an entrant can obtain FDA approval for an equivalent digoxin immune Fab product, not whether a conventional small-molecule generic can easily substitute for DigiFab.
Orange Book-listed patents, if any, would be evaluated against the specific NDA and product listing. The public information cited here does not establish an active Orange Book patent that would create a material near-term barrier to competition.
A competing applicant would face product-specific regulatory work, including:
- Demonstration of identity and potency
- Control of animal-derived raw materials
- Immunogenicity assessment
- Manufacturing consistency
- Sterility and viral-safety controls
- Clinical justification for the intended indication
Which companies are challenging DigiFab?
No major active Paragraph IV litigation or named commercial challenge is established in the sources cited here. The principal competitive threat would come from a manufacturer developing another digoxin immune Fab product or reintroducing a competing ovine Fab product.
Potential entrants would need expertise in biologic-like purification, antibody-fragment manufacturing, emergency-medicine distribution, and FDA approval strategy. Standard generic-drug capabilities alone may not be sufficient.
How strong is the DigiFab patent estate?
The patent estate appears weak to moderate as a current exclusionary tool, while the manufacturing and regulatory position is stronger.
| Barrier |
Relative strength |
Commercial impact |
| Original composition patents |
Low |
Likely expired or commercially immaterial |
| Formulation patents |
Low to moderate |
May affect specific presentations |
| Method-of-use patents |
Low |
Severe toxicity treatment is established |
| Manufacturing know-how |
Moderate to high |
Can delay reliable reproduction |
| FDA product approval |
Moderate |
Requires product-specific evidence |
| Hospital contracts |
Moderate |
Supports retention of market share |
| Supply reliability |
High |
Important in emergency medicine |
| Brand recognition |
Moderate |
Relevant to physician and pharmacy confidence |
The strongest barrier is not a broad patent monopoly. It is the combination of specialized manufacturing, regulatory validation, limited market scale, and the need for dependable emergency supply.
What patent litigation affects DigiFab?
No material active U.S. patent litigation affecting DigiFab is identified in the cited public sources. The absence of litigation is consistent with the product’s mature patent position and limited commercial scale.
Litigation risk could increase if a new entrant obtains FDA approval and launches a competing product. Potential disputes could involve:
- Manufacturing-process patents
- Purification methods
- Formulation stability
- Labeling and method-of-use claims
- Trade secrets
- Contractual supply or distribution rights
At present, litigation risk appears lower than regulatory and manufacturing execution risk.
Are biosimilars a risk to DigiFab?
Biosimilar competition is not the principal risk. DigiFab is an antibody-fragment product derived from ovine immunoglobulin, and its competitive pathway does not resemble the commercial market for large human or humanized monoclonal antibodies.
A competing digoxin immune Fab would more likely enter through a product-specific regulatory route requiring demonstration of quality, potency, safety, and clinical suitability. The market could still experience biologic-like competition, but conventional interchangeable-biosimilar dynamics are not the central issue.
What generic launch scenarios exist for DigiFab?
Scenario 1: No competing launch
SERB retains a concentrated market position. Revenue remains dependent on hospital stocking, price, utilization, and supply performance. This is the most favorable scenario for pricing power.
Scenario 2: Limited specialty competitor
A second product enters selected hospital systems. SERB may preserve share through established contracts, physician familiarity, and supply reliability. Price pressure would be moderate.
Scenario 3: Broad competitive launch
A well-funded entrant secures FDA approval and dependable production. Hospital systems could seek lower prices and dual-source contracts. DigiFab revenue and margins would face the greatest pressure.
Scenario 4: Supply-driven market disruption
If DigiFab supply is interrupted, hospitals may accelerate adoption of an alternative product or revise stocking practices. A temporary shortage could produce short-term revenue displacement and long-term account loss.
How does DigiFab compare with alternative treatments?
DigiFab is used when rapid removal of digoxin from circulation is clinically necessary. Supportive care, activated charcoal in selected cases, electrolyte correction, antiarrhythmic therapy, and temporary pacing may be used in appropriate patients, but these measures do not provide the same mechanism as digoxin immune Fab.
| Treatment approach |
Role |
Direct substitute for DigiFab? |
| Digoxin immune Fab |
Binds and neutralizes digoxin |
Yes, if another approved Fab product is available |
| Activated charcoal |
Limits absorption in selected overdose cases |
No |
| Electrolyte correction |
Manages associated abnormalities |
No |
| Antiarrhythmics |
Controls selected arrhythmias |
No |
| Hemodialysis |
Limited utility for digoxin removal |
Generally no |
| Supportive monitoring |
Manages less severe toxicity |
No |
This limited substitution supports demand resilience in severe cases, although it does not eliminate pressure from declining digoxin use.
What regulatory status and FDA risks affect DigiFab?
DigiFab’s main FDA risks are product quality, manufacturing consistency, labeling compliance, and supply continuity. Because it is an emergency antidote, the commercial impact of a manufacturing observation or shortage can be disproportionate to the product’s sales volume.
Key regulatory considerations include:
- Continued compliance with current good manufacturing practice
- Control of animal-derived materials
- Viral and adventitious-agent controls
- Batch potency and purity
- Stability through the labeled shelf life
- Accurate dosing information
- Adverse-event monitoring
- Reliable availability for emergency use
The product’s mature approval reduces clinical-development risk, but it does not remove manufacturing and quality risk.
What geographic markets matter most for DigiFab?
The United States is the most commercially important market because of its high hospital expenditure, established poison-control infrastructure, and historical reliance on DigiFab and Digibind. International demand depends on national approvals, hospital procurement systems, and availability of competing digoxin immune Fab products.
Geographic expansion is constrained by:
- Country-specific regulatory approval
- Reimbursement rules
- Hospital tendering
- Cold-chain or controlled distribution requirements
- Local digoxin utilization
- Availability of alternative antidotes
A global growth strategy would likely depend more on distribution and regulatory registrations than on new clinical indications.
What licensing deals and commercial transactions involve DigiFab?
The most important disclosed transaction is SERB’s acquisition of BTG’s specialty pharmaceutical business from Boston Scientific. That transaction transferred DigiFab into SERB’s specialty pharmaceutical portfolio.[2][3]
No separate DigiFab licensing agreement is established in the cited sources. The ownership transfer is more relevant to the product’s financial trajectory than a standalone co-development or regional licensing deal.
Key Takeaways
- DigiFab is a mature, hospital-based antidote for severe digoxin toxicity.
- SERB Pharmaceuticals owns the commercial business following the transfer of BTG’s specialty pharmaceutical portfolio from Boston Scientific.
- Product-level revenue and profitability are not publicly disclosed.
- Demand is low volume but clinically essential, supporting high value per treated case.
- Declining digoxin use is a structural demand headwind.
- Severe toxicity, hospital stocking, and limited substitutes support market resilience.
- Original regulatory exclusivity is expired, and no material current patent barrier is established in the cited public record.
- Manufacturing know-how, regulatory compliance, supply reliability, and hospital contracts are stronger barriers than patent exclusivity.
- No major active Paragraph IV challenge, biosimilar threat, or patent litigation is identified in the cited sources.
- The principal commercial risk is a credible competing digoxin immune Fab product combined with hospital price competition.
FAQs About DigiFab Market and Patent Risk
Is DigiFab still commercially available?
DigiFab remains an FDA-approved product for life-threatening or potentially life-threatening digoxin toxicity, subject to commercial supply and hospital distribution conditions.
What company manufactures DigiFab?
SERB Pharmaceuticals is the current owner of the specialty pharmaceutical business that includes DigiFab. The product was previously associated with BTG Pharmaceuticals.
Does DigiFab have a generic equivalent?
The principal competitive possibility is another digoxin immune Fab product, not a conventional small-molecule generic. No major active competing product is established in the sources cited here.
Why is DigiFab expensive if it is an old product?
The cost reflects emergency use, specialized antibody-fragment manufacturing, quality controls, limited volume, hospital inventory requirements, and the absence of routine therapeutic substitutes for severe toxicity.
Can hospital systems replace DigiFab with supportive care?
Supportive care can be appropriate for selected patients, but it is not a direct substitute when rapid neutralization of digoxin is clinically indicated.
References
-
U.S. Food and Drug Administration. (2001). DigiFab (digoxin immune Fab) prescribing information. Drugs@FDA.
-
Boston Scientific Corporation. (2021). Boston Scientific completes sale of BTG specialty pharmaceuticals business to SERB Pharmaceuticals. Boston Scientific investor and corporate communications.
-
SERB Pharmaceuticals. (2021). SERB completes acquisition of BTG specialty pharmaceutical business. SERB Pharmaceuticals corporate announcement.